GSK-3326595
![]() |
- ₹0
- Product name: GSK-3326595
- CAS: 1616392-22-3
- MF: C24H32N6O3
- MW: 452.55
- EINECS:
- MDL Number:MFCD29991177
- Synonyms:EPZ-015938;4-Pyrimidinecarboxamide, 6-[(1-acetyl-4-piperidinyl)amino]-N-[(2S)-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-hydroxypropyl]-;GSK-3326595,EPZ-015938;EPZ-015938 (GSK3326595);4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamid;6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1;EPZ015938; 6-[(1-ACETYLPIPERIDIN-4-YL)AMINO]-N-[(2S)-2-HYDROXY-3-(1;2;3;4-TETRAHYDROISOQUINOLIN-2-YL)PROPYL]PYRIMIDINE-4-CARBOXAMID;EPZ015938; EPZ 015938; EPZ-015938
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Boiling point :760.3±60.0 °C(Predicted)
Density :1.275±0.06 g/cm3(Predicted)
storage temp. :under inert gas (nitrogen or Argon) at 2–8 °C
solubility :Soluble in DMSO (up to 20 mg/ml).
pka :12.44±0.46(Predicted)
form :solid
color :Off-white
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
Density :1.275±0.06 g/cm3(Predicted)
storage temp. :under inert gas (nitrogen or Argon) at 2–8 °C
solubility :Soluble in DMSO (up to 20 mg/ml).
pka :12.44±0.46(Predicted)
form :solid
color :Off-white
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
GSK3326595 (1616395-22-3) is a potent (IC50?= 6.2nM), selective (>4000-fold over 20 other methyltransferases), SAM uncompetitive, peptide competitive inhibitor of PRMT5.1?PRMT5 inhibition activated the p53 pathway?via?induction of alternative splicing of MDM4 leading to a potent anti-proliferative response both?in vitro?and?in vivo. Combination therapy with palbociclib (CDK4/6 inhibitor, Focus Cat.# 10-4760) and GSK3326595 lead to increased efficacy of palbociclib in treating native and resistant models of melanoma via regulation of the PRMT5-MDM4 axis.2?Currently in clinical trials.3More related product prices
2-(2-Methoxyethoxy)ethanol GSK-2881078 GSK2636771 MethanesulfonaMide, N-[5-[4-[5-[[(2R,6S)-2,6-diMethyl-4-Morpholinyl]Methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-Methoxy-3-pyridinyl]-, rel- GSK2982772 GSK-2256098 188591-46-0 GSK481 GSK461364 GSK583 GSK484 1346572-63-1 RET Kinase inhibitor 1Related product price
- 2-(2-Methoxyethoxy)ethanol
₹666-9230 - 188591-46-0
₹16460-68901.13 - GSK484
₹35874.05-137953.8